natgillin/translations-raw huggingface dataset:
This may indicate a potential for rivastigmine transdermal patches to induce mild erythema in patients. 
To može upućivati na mogućnost da transdermalni flasteri s rivastigminom uzrokuju blagi eritem u bolesnika.
The metabolite-to-parent AUC∞ ratio was around 0.7 after transdermal patch administration versus 3.5 after oral administration, indicating that much less metabolism occurred after dermal compared to oral treatment. 
Omjer AUC∞ metabolita u odnosu na osnovni lijek bio je oko 0,7 nakon primjene transdermalnog flastera u usporedbi s 3,5 nakon oralne primjene, što upućuje na znatno smanjeni metabolizam nakon kožnog u usporedbi s oralnim liječenjem.
- Then press the patch firmly in place for at least 30 seconds using the palm of the hand to make sure that the edges stick well. 
- Zatim dlanom čvrsto pritisnite flaster najmanje 30 sekundi kako biste bili sigurni da su se rubovi dobro zalijepili.
You may become dehydrated (losing too much fluid) if vomiting or diarrhoea are prolonged. 
(izgubiti previše tekućine) ako povraćanje ili proljev potraju.
The inter-patient variability in a steady-state study in Alzheimer's dementia was at most 45% (Cmax) and 43% (AUC0-24h) after use of the transdermal patch, and 71% and 73%, respectively, after administration of the oral form. 
Varijabilnost između bolesnika s Alzheimerovom demencijom u stanju dinamičke ravnoteže bila je najviše 45% (Cmax) i 43% (AUC0-24h) nakon primjene transdermalnog flastera te 71% i 73% nakon primjene oralne
PHARMACEUTICAL PARTICULARS 
FARMAKOLOŠKA SVOJSTVA
After oral administration, Cmax and AUC of rivastigmine were more than twice as high in Alzheimer patients with moderate renal impairment compared with healthy subjects; however there were no changes in Cmax and AUC of rivastigmine in Alzheimer patients with severe renal impairment. 
Nakon oralne primjene Cmax i AUC rivastigmina bili su više nego dvostruko veći u ispitanika s umjerenim oštećenjem bubrega; no, u ispitanika s Alzheimerovom bolešću s teškim oštećenjem bubrega nije bilo promjena u Cmax i AUC vrijednostima rivastigmina.
These include the ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive subscale, a performance-based measure of cognition) and the ADCS-CGIC (Alzheimer's Disease Cooperative Study - Clinician's Global Impression of Change, a comprehensive global assessment of the patient by the physician incorporating caregiver input), and the ADCS-ADL (Alzheimer's Disease Cooperative StudyActivities of Daily Living, a caregiver-rated assessment of the activities of daily living including personal hygiene, feeding, dressing, household chores such as shopping, retention of ability to orient oneself to surroundings as well as involvement in activities related to finances). 
Alzheimer's Disease Assessment Scale - kognitivna podljestvica, mjerilo kognitivne sposobnosti koje se temelji na izvedbi) i ADCS-CGIC (sveobuhvatna globalna procjena bolesnika od strane liječnika koja uključuje podatke dobivene od njegovatelja), te ADCS-ADL (njegovateljeva procjena svakodnevnih aktivnosti, uključujući osobnu higijenu, hranjenje, oblačenje, poslove vezane za domaćinstvo kao što su odlazak u kupovinu, očuvanje sposobnosti orijentiranja u okolini, kao i uključivanje u aktivnosti koje se odnose na financije).
Patients and caregivers should be instructed on important administration instructions: - The previous day's patch must be removed before applying a new one every day (see section 4.9). 
Bolesnici i njegovatelji trebaju dobiti važne upute o primjeni: - Flaster od prethodnog dana mora se ukloniti prije primjene novog flastera svakog dana (vidjeti dio - Flaster treba zamijeniti novim nakon 24 sata.
What Rivastigmine 3M Health Care Ltd. is and what it is used for 
Što je Rivastigmin 3M Health Care Ltd. i za što se koristi
Rectangular patches, approximately 2.5 cm by 1.8 cm with rounded corners. 
Pravokutni flasteri zaobljenih kuteva, približnih dimenzija 2,5 cm s 1,8 cm.
Nausea, vomiting, diarrhoea, dyspepsia, abdominal pain 
Mučnina, povraćanje, proljev, dispepsija, bol u abdomenu
ADCS-CGIC 
Rezultati na ADCS-CGIC-u
The study was designed to compare the efficacy of the 13.3 mg/24 h transdermal patch against the 9.5 mg/24 h transdermal patch during a 48-week double-blind treatment phase in Alzheimer's disease patients who demonstrated functional and cognitive decline after an initial 24-48 week openlabel treatment phase while on a maintenance dose of 9.5 mg/24 h transdermal patch. 
Ispitivanje je bilo osmišljeno da bi se usporedila djelotvornost transdermalnog flastera u dozi od 13,3 mg/24 h s onim u dozi od 9,5 mg/24 h tijekom 48-tjedne faze dvostruko slijepog liječenja u bolesnika s Alzheimerovom bolešću u kojih je potvrđeno funkcionalno i kognitivno pogoršanje nakon početne faze otvorenog liječenja u trajanju od 24-48 tjedna, za vrijeme primjene doze održavanja u obliku 9,5 mg/24 h transdermalnog flastera.
In peri/postnatal studies in rats, an increased gestation time was observed. 
U ispitivanjima u štakora tijekom i nakon trudnoće, primijećeno je produljenje vremena gestacije.
Contact with the eyes should be avoided after handling Rivastigmine 3M Health Care Ltd. transdermal patches (see section 5.3). 
Potrebno je izbjegavati kontakt s očima nakon rukovanja Rivastigmin 3M Health Care Ltd. transdermalnim flasterima (vidjeti dio 5.3).
There was no relevant accumulation of rivastigmine or the metabolite NAP226-90 in plasma in patients with Alzheimer's disease, except that plasma levels were higher on the second day of transdermal patch therapy than on the first. 
U plazmi bolesnika s Alzheimerovom bolešću nije bilo značajnog nakupljanja rivastigmina ili metabolita NAP226-90, osim što su razine plazme bile više drugog dana liječenja transdermalnim flasterom nego
Special populations - Paediatric population: There is no relevant use of Rivastigmine 3M Health Care Ltd. in the paediatric population in the treatment of Alzheimer's disease. 
- Pedijatrijska populacija: Nema relevantne primjene lijeka Rivastigmin 3M Health Care Ltd. u pedijatrijskoj populaciji u liječenju Alzheimerove bolesti.
However, due to increased exposure in these populations as observed with the oral forms, dosing recommendations to titrate according to individual tolerability should be closely followed as patients with clinically significant renal impairment might experience more adverse reactions (see sections 4.4 and 5.2). 
Međutim, u ovih skupina bolesnika, zbog veće izloženosti, koja je bila uočena kod oralnih formulacija, nužno je pažljivo pratiti preporuke o doziranju glede titriranja prema individualnoj podnošljivosti, jer bolesnici s klinički značajnim oštećenjem bubrega mogu razviti više nuspojava (vidjeti dijelove 4.4 i 5.2).
- Store in the original package in order to protect from light. 
- Čuvati u originalnom pakiranju radi zaštite od svjetlosti.
The single-dose inter-subject variability in rivastigmine pharmacokinetic parameters (normalised to dose/kg bodyweight) was 43% (Cmax) and 49% (AUC0-24h) after transdermal administration versus 74% and 103%, respectively, after the oral form. 
Varijabilnosti između pojedinih ispitanika s obzirom na farmakokinetičke parametre rivastigmina nakon jednokratne doze (prilagođeno prema dozi/kg tjelesne težine) bila je 43% (Cmax) i 49% (AUC024h) nakon transdermalne primjene u usporedbi s 74% i 103% nakon oralne primjene.
If you have not applied a patch for several days, do not apply the next one before you have talked to your doctor. 
Ako nekoliko dana niste stavljali flaster, sljedeći flaster nemojte stavljati dok se ne posavjetujete sa
The efficacy of rivastigmine transdermal patches in patients with Alzheimer's dementia has been demonstrated in a 24-week double-blind, placebo-controlled core study and its open-label extension phase and in a 48-week double-blind comparator study. 
Djelotvornost transdermalnih flastera s rivastigminom u bolesnika s Alzheimerovom demencijom dokazana je u 24-tjednom dvostruko slijepom, placebom kontroliranom osnovnom ispitivanju i u njegovom otvorenom produžetku te u 48-tjednom dvostruko slijepom ispitivanju s komparatorom.
Oral studies in pregnant rats and rabbits gave no indication of teratogenic potential on the part of rivastigmine. 
U ispitivanjima peroralne primjene lijeka na skotnim ženkama štakora i kunića nije bilo naznaka teratogenog potencijala rivastigmina.
In the 24-week doubleblind study, the most commonly observed symptoms (skin irritation rating scale) with rivastigmine 9.5 mg/24 h transdermal patches were very slight (21.8%), mild (12.5%) or moderate (6.5%) erythema or very slight (11.9%), mild (7.3%) or moderate (5.0%) pruritus. 
U 24-tjednom dvostruko slijepom ispitivanju, najučestalije opaženi simptomi (prema ocjenskoj ljestvici nadražaja kože) s transdermalnim flasterima s rivastigminom u dozi od 9,5 mg/24 h bili su vrlo blagi (21,8%), blagi (12,5%) ili umjereni (6,5%) eritem ili vrlo blagi (11,9%), blagi (7,3%) ili umjereni (5,0%) pruritus.
Carefully remove the existing patch before putting on a new one. 
Pažljivo skinite postojeći flaster prije nego što postavite novi.
Rare (may affect up to 1 in 1,000 people) - Falling 
Vrlo rijetko (mogu se javiti u do 1 na 10 000 ljudi)
Rivastigmine 9.5 mg/24 h N = 271 
Rivastigmin 9,5 mg/24 h N=271
The most commonly observed severe symptoms with rivastigmine 9.5 mg/24 h transdermal patches were pruritus (1.7%) and erythema (1.1%). 
Najučestalije opaženi teški simptomi s transdermalnim flasterima s rivastigminom u dozi od 9,5 mg/24 h bili su pruritus (1,7%) i eritem (1,1%).
Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2). 
Lijek se izdaje na ograničeni recept (vidjeti dodatak I: Sažetak opisa svojstava lijeka, dio 4.2).
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS POUCH 
PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE VREĆICA
No pharmacokinetic interaction was observed between oral rivastigmine and digoxin, warfarin, diazepam or fluoxetine in studies in healthy volunteers. 
U ispitivanjima na zdravim dobrovoljcima nije zapažena farmakokinetička interakcija između oralnog rivastigmina i digoksina, varfarina, diazepama ili fluoksetina.
There have been rare post-marketing reports of patients experiencing disseminated skin hypersensitivity reactions when administered rivastigmine irrespective of the route of administration (oral, transdermal). 
Poslije stavljanja lijeka u promet, zabilježene su rijetke pojave diseminirane reakcije kožne preosjetljivosti u bolesnika kod primjene rivastigmina, neovisno o putu primjene (peroralno, transdermalno).
Patients and their caregivers must be instructed on important administration instructions for Rivastigmine 3M Health Care Ltd. transdermal patch (see section 4.2). 
Bolesnici i njihovi njegovatelji moraju dobiti važne upute o primjeni Rivastigmin 3M Health Care Ltd. transdermalnog flastera (vidjeti dio 4.2).
How to remove your Rivastigmine 3M Health Care Ltd. transdermal patch Gently pull at one edge of the patch to remove it slowly from the skin. 
Kako skinuti Rivastigmin 3M Health Care Ltd. transdermalni flaster Lagano povucite jedan kraj flastera kako biste ga polako skinuli s kože.
Each patch is sealed in a pouch that protects it until you are ready to put it on. Do not open the pouch or remove a patch until just before you apply it. 
Svaki je flaster zapakiran u vrećicu koja ga štiti do trenutka kada ste spremni postaviti ga.
- Only wear one Rivastigmine 3M Health Care Ltd. patch at a time and replace the patch with a new one after 24 hours. 
Potrebno je primijeniti samo jedan Rivastigmin 3M Health Care Ltd. flaster koji ćete zamijeniti novim flasterom nakon 24 sata.
SPECIAL STORAGE CONDITIONS Store in the original package in order to protect from light. 
POSEBNE MJERE ČUVANJA Čuvati u originalnom pakiranju radi zaštite od svjetlosti.
Slow heartbeat and fainting may also occur. 
Također može doći do usporenih otkucaja srca i nesvjestice.
If you have to undergo surgery whilst using Rivastigmine 3M Health Care Ltd. transdermal patches, tell your doctor that you are using them because they may exaggerate the effects of some muscle relaxants during anaesthesia. 
Ako se, tijekom primjene Rivastigmin 3M Health Care Ltd. transdermalnih flastera, morate podvrgnuti operaciji obavijestite svog liječnika da ih koristite jer oni mogu tijekom anestezije pojačati učinke
Very rare (may affect up to 1 in 10,000 people) - High blood pressure - Inflammation of the pancreas - the signs include serious upper stomach pain, often with feeling sick (nausea) or being sick (vomiting) - Bleeding in the gut - shows as blood in stools or when being sick - Seeing things that are not there (hallucinations) - Some people who have been violently sick have had tearing of the tube that connects your mouth with your stomach (oesophagus) 
Vrlo rijetko (mogu se javiti u do 1 na 10 000 ljudi) - Upala gušterače - znakovi uključuju jaku bol u gornjem dijelu trbuha, često s osjećajem - Krvarenje u crijevu - prikazuje se kao krv u stolici ili kada povraćate - U nekih je bolesnika koji su imali izrazitu mučninu došlo do pucanja cijevi koja povezuje Vaša
How to apply your Rivastigmine 3M Health Care Ltd. transdermal patch Rivastigmine 3M Health Care Ltd. patches are transparent to translucent, plastic patches that stick to the skin. 
Kako staviti Rivastigmin 3M Health Care Ltd. transdermalni flaster Rivastigmin 3M Health Care Ltd. flasteri su prozirni do zamućeni, plastični flasteri koji se lijepe na kožu.
After a minimum of four weeks of treatment and if well tolerated according to the treating physician, the dose of 4.6 mg/24 h should be increased to 9.5 mg/24 h, the daily recommended effective dose, which should be continued for as long as the patient continues to demonstrate therapeutic benefit. 
Nakon najmanje četiri tjedna liječenja te ako se lijek prema mišljenju liječnika dobro podnosi, dozu od 4,6 mg/24 h potrebno je povećati na 9,5 mg/24 h, dnevnu preporučenu djelotvornu dozu, s kojom treba nastaviti dokle god bolesnik od toga ima terapijsku korist.
Store in the original package in order to protect from light. 
Čuvati u originalnom pakiranju radi zaštite od svjetlosti.
Do not use Rivastigmine 3M Health Care Ltd. - if you are allergic to rivastigmine or any of the other ingredients of this medicine (listed in section 6). 
- Ako ste alergični na rivastigmin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
Dehydration 
Možete dehidrirati
If you use more Rivastigmine 3M Health Care Ltd. than you should If you accidentally apply more than one patch, remove all the patches from your skin, then inform your doctor that you have accidentally applied more than one patch. 
Ako ste zabunom stavili više od jednog flastera, skinite sve flastere sa svoje kože i obavijestite liječnika da ste slučajno stavili više od jednog flastera.
If the oral dose of 9 mg/day has not been stable and well tolerated, a switch to 4.6 mg/24 h transdermal patches is recommended. 
Ako oralna doza od 9 mg/dan nije bila stabilna i nije se dobro podnosila, preporučuje se prebacivanje na transdermalni flaster u dozi od
After switching to 4.6 mg/24 h transdermal patches, provided these are well tolerated after a minimum of four weeks of treatment, the dose of 4.6 mg/24 h should be increased to 9.5 mg/24 h, which is the recommended effective dose. 
Nakon prijelaza na transdermalni flaster u dozi od 4,6 mg/24 h, pod uvjetom da se dobro podnosi nakon najmanje četiri tjedna liječenja, dozu od 4,6 mg/24 h potrebno je povećati na 9,5 mg/24 h, što je
Rivastigmine 13.3 mg/24 h N = 265 
Rivastigmin 13,3 mg/24 h N=265
The fluctuation index (FI), a measure of the relative difference between peak and trough concentrations ((Cmax-Cmin)/Cavg), was 0.58 for rivastigmine 4.6 mg/24 h transdermal patches, 0.77 for rivastigmine 9.5 mg/24 h transdermal patches and 0.72 for rivastigmine 13.3 mg/24 h transdermal patches, thus demonstrating a much smaller fluctuation between trough and peak concentrations than for the oral formulation (FI = 3.96 (6 mg/day) and 4.15 (12 mg/day)). 
Indeks fluktuacije (FI), mjera relativne razlike između vršne i najniže koncentracije ((Cmax-Cmin)/Cavg), bio je 0,58 za transdermalne flastere s 4,6 mg/24 h rivastigmina, 0,77 za transdermalne flastere s 9,5 mg/24 h rivastigmina i 0,72 za transdermalne flastere s 13,3 mg/24 h rivastigmina, čime se potvrđuje puno manja fluktuacija između najniže i vršne koncentracije nego kod oralne formulacije (FI = 3,96 (6 mg/dan) i 4,15 (12 mg/dan)).
Therefore, in patients with dementia treated with rivastigmine, the ability to continue driving or operating complex machines should be routinely evaluated by the treating physician. 
Zbog toga u bolesnika s demencijom, koji se liječe rivastigminom, liječnik treba rutinski procjenjivati mogu li nastaviti upravljati vozilima ili raditi sa složenim strojevima.
Patients involved in the placebo-controlled study had an MMSE (Mini-Mental State Examination) score of 10-20. 
MiniMental State Examination - Skraćeni pregled mentalnog stanja) od 10-20.
The increase in prothrombin time induced by warfarin is not affected by administration of oral rivastigmine. 
Primjena oralnog rivastigmina ne utječe na povećanje protrombinskog vremena koje inducira varfarin.
Rivastigmine is an acetyl- and butyrylcholinesterase inhibitor of the carbamate type, thought to facilitate cholinergic neurotransmission by slowing the degradation of acetylcholine released by functionally intact cholinergic neurones. 
Farmakoterapijska skupina: psihoanaleptici, antikolinesteraze, ATK oznaka: N06DA03 Rivastigmin je inhibitor acetilkolinesteraze i butirilkolinesteraze karbamatnog tipa, za kojeg se smatra da olakšava kolinergičku neurotransmisiju usporavanjem razgradnje acetilkolina kojeg otpuštaju funkcionalno intaktni kolinergički neuroni.
Can you wear your Rivastigmine 3M Health Care Ltd. transdermal patch when you are bathing, swimming, or in the sun? 
Možete li nositi Rivastigmin 3M Health Care Ltd. transdermalni flaster dok se kupate, plivate ili - Kupanje, plivanje ili tuširanje ne bi trebalo utjecati na flaster.
Make sure the patch does not loosen during these activities. 
Pazite da se flaster ne odlijepi
After oral administration, the Cmax of rivastigmine was approximately 60% higher and the AUC of rivastigmine was more than twice as high in subjects with mild to moderate hepatic impairment than in healthy subjects. 
Nakon oralne primjene, Cmax rivastigmina bio je oko 60% veći, a AUC rivastigmina bila je više nego dvostruko veća u ispitanika s blagim do umjerenim oštećenjem jetre, nego u zdravih
What you need to know before you use Rivastigmine 3M Health Care Ltd. 
Što morate znati prije nego počnete primjenjivati Rivastigmin 3M Health Care Ltd.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each transdermal patch releases 4.6 mg of rivastigmine per 24 hours. 
KVALITATIVNI I KVANTITATIVNI SASTAV Jedan transdermalni flaster oslobađa 4,6 mg rivastigmina u 24 sata.
Not known (frequency cannot be estimated from the available data) - Allergic reaction where the patch was used, such as blisters or inflamed skin - The signs of Parkinson's disease get worse - such as tremor, stiffness and shuffling - Inflammation of the pancreas - signs include serious upper stomach pain, often with feeling sick 
Nepoznato (učestalost nuspojava ne može se procijeniti iz dostupnih podataka) - Alergijska reakcija na mjestu primjene flastera, kao što su mjehurići ili upala kože - Pogoršanje znakova Parkinsonove bolesti - kao što su nevoljno drhtanje, ukočenost i poteškoće pri kretanju
- if you have gastrointestinal reactions such as feeling sick (nausea), being sick (vomiting) and diarrhoea. 
- ako imate probavne reakcije poput osjećaja mučnine, povraćanje i proljeva.
Special populations: - Patients with body weight below 50 kg may experience more adverse reactions and may be more likely to discontinue due to adverse reactions (see section 4.2). 
- Bolesnici s tjelesnom težinom manjom od 50 kg mogu imati više nuspojava te je vjerojatnije da će prekinuti liječenje zbog nuspojava (vidjeti dio 4.2).
Rectangular patches, approximately 3.5 cm by 2.6 cm with rounded corners. 
Pravokutni flasteri zaobljenih kuteva, približnih dimenzija 3,5 cm s 2,6 cm.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each transdermal patch releases 9.5 mg of rivastigmine per 24 hours. 
KVALITATIVNI I KVANTITATIVNI SASTAV Jedan transdermalni flaster oslobađa 9,5 mg rivastigmina u 24 sata.
Each patch consists of a combination of a removable, transparent, split release liner, a functional layer containing drug-inadhesive (DIA) matrix, and a protective backing layer. 
Jedan transdermalni flaster sastoji se od sljedeće kombinacije: odvojive, transparentne zaštitne folije koja se može skinuti, funkcionalnog sloja koji sadrži lijek u adhezivnom matriksu i zaštitnog potpornog sloja.
*A marketing authorisation for Rivastigmine 3M Health Care Ltd. 13.3 mg/24 h transdermal patch is currently not available, this presentation may although be available from other marketing authorisation holders. 
13,3 mg/24 h trenutno nije dostupno, iako ova doza može biti dostupna od drugih nositelja odobrenja.
- Do not use this medicine after the expiry date, which is stated on the carton and pouch after 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i vrećici iza Rok valjanosti/EXP.
Initial dose Treatment is started with 4.6 mg/24 h. 
Početna doza Liječenje se započinje dozom od 4,6 mg/24 h.
No specific interaction studies have been performed with Rivastigmine 3M Health Care Ltd. transdermal patches. 
Nisu provedena specifična ispitivanja interakcija s Rivastigmin 3M Health Care Ltd. transdermalnim flasterima.
To prevent interference with the adhesive properties of the transdermal patch, no cream, lotion or powder should be applied to the skin area where the medicinal product is to be applied. 
Radi sprječavanja ometanja ljepljivih svojstava transdermalnog flastera, na površinu kože na koju će se primijeniti lijek ne smije se nanositi krema, losion ili puder.
LIST OF EXCIPIENTS Also contains polyester, ethyl vinyl acetate, acrylate copolymer adhesive and isopropyl myristate. 
Također sadrži poliester, etilvinilacetat, ljepilo od akrilatnog kopolimera i izopropil miristat.
• Instructions to provide patients and caregivers with the patient reminder card The patient reminder card should contain the following key messages: 
• Upute o davanju kartice s podsjetnikom za bolesnika bolesnicima i njegovateljima
Each transdermal patch of 8.3 cm2 contains 14.33 mg of rivastigmine. 
Jadan transdermalni flaster površine 8,3 cm2 sadrži 14,33 mg rivastigmina.
- The other ingredients are polyester, ethyl vinyl acetate, acrylate copolymer adhesive and isopropyl myristate. 
Drugi sastojci su poliester, etilvinilacetat, ljepilo od akrilatnog kopolimera i izopropil miristat.
For patients starting treatment for the first time and for patients restarting Rivastigmine 3M Health Care Ltd. after treatment interruption, please begin with the second picture. 
Za bolesnike koji po prvi put počinju liječenje i za bolesnike koji ponovno počinju primjenjivati Rivastigmin 3M Health Care Ltd.
Each transdermal patch of 4.15 cm2 contains 7.17 mg of rivastigmine. 
Jadan transdermalni flaster površine 4,15 cm2 sadrži 7,17 mg rivastigmina.
Patients involved in the active comparator controlled study had an initial baseline MMSE score of 10-24. 
48-tjedno aktivno kontrolirano ispitivanje s komparatorom Bolesnici uključeni u aktivno kontrolirano ispitivanje s komparatorom imali su početni rezultat na MMSE-u od 10-24.
Otherwise treatment should be re-initiated with 4.6 mg/24 h. 
U suprotnom, liječenje treba ponovno započeti pri dozi od 4,6 mg/24 h.
Polyester and ethyl vinyl acetate 
Potporni sloj: poliester i etilvinilacetat
If you are pregnant, the benefits of using Rivastigmine 3M Health Care Ltd. transdermal patches must be assessed against the possible effects on your unborn child. Rivastigmine 3M Health Care Ltd. should not be used during pregnancy unless clearly necessary. 
Ako ste trudni, potrebno je ocijeniti koristi od uporabe Rivastigmin 3M Health Care Ltd. transdermalnih flastera u usporedbi s mogućim učincima na Vaše nerođeno dijete.